Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||no benefit||AT-101 + Bicalutamide||Phase I||Actionable||In a Phase I trial, the combination of AT-101 and Casodex (bicalutamide) resulted in an undetectable PSA in 31% (17/55) of patients with castration resistant prostate cancer, however, the percentage did not reach the prespecified level and thus, the theraputic combination will not be pursued further (PMID: 26476589).||26476589|